Treatment of Personality Disorders: Clusters A, B, and C

General Principles Across All Personality Disorders

1. Stabilization phase - reduce acute distress, dangerous behaviors, and conflict using targeted pharmacotherapy and basic psychotherapy
2. Awakening phase - cultivate self-awareness and a positive outlook through psychoeducation and experiential therapies
3. Advanced phase - address the root causes of symptoms (lack of self-respect, trust deficits, maladaptive cognitions) using an integrated multimodal approach

CLUSTER A - "Odd/Eccentric"

1. Paranoid Personality Disorder

• Individual psychotherapy is the primary treatment. The therapist must be straightforward and honest in all dealings. If the patient accuses the therapist of inconsistency or lateness, honesty and a direct apology are preferable to a defensive explanation.
• A professional, not overly warm style is required - warmth can increase mistrust.
• Avoid overzealous interpretation of deep feelings of dependence, sexual concerns, or wishes for intimacy, as this significantly increases mistrust.
• Group therapy is generally poorly tolerated due to the intrusiveness patients experience; can be cautiously used for social skills training and reducing suspiciousness via role-playing.
• Behavior therapy for social skills training is often intolerable due to its intrusive nature.
• When patients behave threateningly, therapists must set limits clearly. Never offer to take control unless willing and able - these patients are profoundly frightened by weakness in those trying to help them.
• Delusional accusations should be handled realistically but gently, without humiliating the patient.

• No FDA-approved agents; evidence is limited.
• Low-dose novel (atypical) antipsychotics (e.g., quetiapine, aripiprazole) for psychotic symptoms or ideas of reference.
• Anticonvulsants (e.g., valproate, carbamazepine) for irritability and aggression.
• Benzodiazepines are generally not recommended due to high risk of dependence and abuse.

2. Schizoid Personality Disorder

• Similar principles to paranoid PD treatment.
• Patients tend toward introspection - this is consistent with psychotherapy and should be respected rather than challenged.
• As trust develops, patients may reveal a rich internal world of fantasies, imaginary friends, and fears of dependency or merging with the therapist.
• Group therapy: Patients may be silent for long periods, but do become involved over time. They must be protected from aggressive attack by group members for their silence. The group may eventually become their only social contact.
• Key therapeutic stance: maintain a quiet, reassuring, considerate interest without insisting on reciprocal response. Respect for their eccentric ways is both therapeutic and necessary.

• Limited evidence.
• Psychotropics targeted at social and emotional detachment may be appropriate.
• Low-dose antipsychotics (aripiprazole, olanzapine, low-dose clozapine, sulpiride) for blunted affect and chronic asociality.

3. Schizotypal Personality Disorder

• Principles do not differ substantially from schizoid PD treatment.
• Clinicians must be especially sensitive and avoid ridiculing or judging the patient's odd beliefs.
• Patients may be involved in cults, strange religious practices, or the occult - these must be explored respectfully.
• Cognitive-behavioral therapy (CBT) can target ideas of reference and social anxiety.

• Antipsychotic medications (low-dose atypicals) are useful for ideas of reference, illusions, magical thinking, and other cognitive-perceptual symptoms. This is the most pharmacologically active cluster A disorder.
• Antidepressants (SSRIs) are useful when a significant depressive component is present.
• Brief reactive psychoses that complicate schizotypal PD are treated with low-dose second-generation antipsychotics; medications should be tapered once stressors are under control.
• Note: schizotypal symptoms are now recognized as part of the schizophrenia spectrum - this informs pharmacological management.

CLUSTER B - "Dramatic/Erratic"

4. Antisocial Personality Disorder (ASPD)

• Evidence is limited but suggests these individuals respond better to contingency management and reward-based interventions than to CBT alone.
• Setting clear limits on behavior is essential.
• Confrontational approaches tend to fail - patients are skilled at manipulation and often engage in "pseudotherapy."
• In some settings (e.g., therapeutic communities, correctional settings), structured group interventions may offer modest benefit.

• Primarily symptomatic - targeting aggression, rage, anxiety, and depression.
• Because patients commonly misuse substances, medications must be prescribed judiciously.
• Anticonvulsants (carbamazepine, valproate) for aggressive behaviors, especially when EEG abnormalities are present.
• Beta-adrenergic antagonists (propranolol), lithium, and antipsychotics may reduce aggression.
• For predatory (cold-blooded) aggression: no effective pharmacologic treatment is established.
• For affective (hot-tempered) aggression with normal EEG: lithium, SSRIs, anticonvulsants, low-dose antipsychotics.
• Benzodiazepines are not recommended - risk of disinhibition and abuse.

5. Borderline Personality Disorder (BPD)

• Developed by Marsha Linehan; combines individual therapy, skills training groups, phone coaching, and therapist consultation.
• Skills taught: mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness.
• Strong evidence for reducing self-harm, suicidality, and hospitalizations.

• Developed by Bateman and Fonagy.
• Focuses on improving the patient's capacity to understand mental states (their own and others').
• Delivered in individual and group formats.
• Good evidence for reducing self-harm and improving interpersonal functioning.

• Psychodynamic therapy focusing on the therapeutic relationship as a microcosm of the patient's interpersonal world.
• Targets identity diffusion and splits in object relations.
• Comparable outcomes to DBT and MBT.

• Medicalizes BPD as a treatable diagnosis. Suitable for clinicians not trained in specialized therapies.
• Key tasks: diagnostic disclosure, psychoeducation, goal setting, safety management, comorbidity treatment, conservative prescribing.
• Applicable in inpatient units, emergency departments, and general health care settings.
• Emphasizes that BPD behaviors are symptoms of a disorder, not willful manipulation - this reframing reduces clinician frustration.

• No FDA-approved medication for BPD. No pharmacotherapy has shown consistent superiority over placebo.
• Medications are used for symptom domains, not the disorder itself:

• Recent 2026 network meta-analysis (PMID: 41667836) assessed pharmacological treatments in BPD - findings may refine specific agent selection; monitoring this emerging literature is advised.

6. Histrionic Personality Disorder

• Psychoanalytic/psychodynamic therapy is the treatment of choice - helps patients understand their attention-seeking and dependency needs.
• Therapists must be mindful of erotic transference; seductive behavior should be addressed as a symptom rather than acted upon or avoided entirely.
• CBT can target the tendency toward dramatic thinking ("catastrophizing") and help build more stable self-esteem not reliant on external attention.
• Group therapy can be useful but requires management of the patient's tendency to dominate sessions.

• Symptomatic treatment based on dominant complaints.
• SSRIs/SNRIs for depression (common comorbidity) and emotional dysregulation.
• Low-dose antipsychotics for brief reactive psychotic episodes or severe emotional dysregulation.
• No specific agents are first-line; treat target symptoms (anxiety, depression, mood lability) per the general PD pharmacotherapy table.

7. Narcissistic Personality Disorder (NPD)

• Among the most difficult PDs to treat due to profound reluctance to examine vulnerabilities.
• Psychoanalytic/psychodynamic therapy is the mainstay - addresses the underlying fragile self-esteem hidden by the grandiose facade, and the frequent experience of narcissistic injury.
• Kohut's self-psychology approach: therapist uses empathic mirroring and gradually helps the patient develop a more realistic self-concept.
• Kernberg's approach (TFP-derived): confronts the grandiose self-structure directly.
• CBT can target specific maladaptive beliefs ("I am exceptional and deserve special treatment").
• Schema therapy addresses early maladaptive schemas (e.g., entitlement/grandiosity schema).
• Patients are prone to premature dropout when confronted with their own vulnerabilities - maintaining the therapeutic alliance is critical.

• No specific pharmacotherapy.
• Treat comorbidities: SSRIs for depression (high comorbidity, especially after narcissistic injuries); SSRIs or mood stabilizers for mood dysregulation and irritability.
• Substance use disorders (especially cocaine) are common comorbidities requiring parallel treatment.

CLUSTER C - "Anxious/Fearful"

8. Avoidant Personality Disorder

• CBT is the treatment of choice - targets negative automatic thoughts about social rejection, builds graduated exposure to feared social situations.
• Systematic desensitization and social skills training are effective components.
• Group therapy is particularly valuable once individual therapy has achieved some initial gains - provides a safe environment to practice social interaction.
• Psychodynamic therapy to address underlying shame and fear of rejection.

• Strong overlap with social anxiety disorder; treatments effective for social phobia apply.
• SSRIs (e.g., sertraline, paroxetine, fluvoxamine) - first-line.
• SNRIs (venlafaxine).
• MAOIs - effective but limited by side effect and dietary restriction burden.
• Beta-blockers (propranolol) for performance anxiety component.
• Pregabalin/GABA analogs for somatic anxiety.

9. Dependent Personality Disorder

• Individual psychotherapy is the treatment of choice.
• CBT helps identify and challenge the core belief of helplessness and incompetence.
• Goals include increasing autonomy, assertiveness, and independent decision-making.
• The therapeutic relationship itself may become the focus - patients will tend to become dependent on the therapist, which must be interpreted and worked through rather than gratified.
• Insight-oriented therapy helps patients understand the origins of their dependency needs.
• Group therapy and assertiveness training are useful adjuncts.
• Avoid premature termination - these patients react poorly to loss of the therapeutic relationship.

• Treat comorbidities (major depression, anxiety disorders are common).
• SSRIs for depression and anxiety.
• Avoid prescribing medications in a way that reinforces the patient's dependency - the prescribing relationship itself can become a vehicle for dependence.
• Benzodiazepines should be avoided or used only briefly given abuse potential and reinforcement of avoidant coping.

10. Obsessive-Compulsive Personality Disorder (OCPD)

• Psychoanalytic/psychodynamic therapy is the classical treatment - addresses anal-retentive character structure, underlying ambivalence, and the defense of isolation (separation of affect from thought).
• CBT targets perfectionism, all-or-nothing thinking, and difficulty tolerating uncertainty.
• Therapists must tolerate patients' intellectualization and excessive attention to detail without reinforcing it.
• The patient's tendency to control the therapeutic relationship must be recognized and interpreted.
• Relapse rates are high without sustained therapy.

• Less pharmacologically responsive than OCD.
• SSRIs for obsessional rumination and when comorbid OCD is present or suspected.
• Clomipramine (TCA) for severe obsessional features.
• Quetiapine as augmentation for obsessions.
• Mood stabilizers (lithium, lamotrigine) if significant emotional lability or depressive features.
• Avoid benzodiazepines long-term.

Cross-Cutting Pharmacotherapy Summary

• Medications are temporary stabilizers - never substitutes for psychotherapy.
• Use should be considered for tapering once self-awareness and self-regulation improve.
• Benzodiazepines carry high risk of dependence and abuse across all PDs - generally not recommended for long-term use.
• Patients with PDs show high prevalence of side effects, idiosyncratic reactions, impatience for benefits, and impulsive decisions about medications.

Recent Evidence

• Digital interventions for BPD (PMID: 39612494, 2024) - systematic review showing emerging digital/app-based DBT-informed tools show promise for BPD symptom reduction.
• Pharmacology in BPD - network meta-analysis (PMID: 41667836, Molecular Psychiatry 2026) - most current systematic review of pharmacological safety and efficacy in BPD; clinicians should consult this for updated agent-specific guidance.
• Clozapine has been examined transdiagnostically (PMID: 41192460, Lancet Psychiatry 2025) for psychotic, affective, and personality disorders, with comparative data vs. other antipsychotics.